Randomized study of ACVBP [doxorubicin + cyclophosphamide + vindesine + bleomycin + prednisone] versus ACVBP plus rituximab in previously untreated patients aged from 18 to 65 years with low-risk localized diffuse large B-cell lymphoma (Age-Adjusted IPI = 0).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rituximab (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Vindesine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 13 Mar 2017 Biomarkers information updated
- 12 Dec 2012 Interim results published in Annals of Oncology.
- 03 Mar 2011 Additional lead trial centers and investigators identified as reported by ClinicalTrials.gov.